NCT01636908View on ClinicalTrials.gov

Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

NACompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

January 1, 2018

Study Completion Date

December 1, 2019

Conditions
CancerAdvanced Solid Tumors
Interventions
DRUG

Sunitinib

50 mg once daily, oral use, 14 days

DRUG

Sorafenib

400 mg, twice daily, oral use, 14 days

DRUG

Erlotinib

150 mg once daily, oral use, 14 days

DRUG

Everolimus

10 mg once daily, oral use, 14 days

DRUG

Lapatinib

1250 mg once daily, oral use, 14 days

DRUG

Dasatinib

100 mg once daily, oral use, 14 days

DRUG

Pazopanib

800 mg once daily, oral use, 14 days

DRUG

Vemurafenib

960 mg twice daily, oral use, 15-21 days

PROCEDURE

tumor biopsy

PROCEDURE

skin biopsy (optional)

Trial Locations (1)

1081 HV

VUMedical Center, Amsterdam

All Listed Sponsors
lead

Amsterdam UMC, location VUmc

OTHER

NCT01636908 - Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. | Biotech Hunter | Biotech Hunter